Universal Beteiligungs und Servicegesellschaft mbH Has $3.68 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 10.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 78,732 shares of the company’s stock after purchasing an additional 7,421 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Revolution Medicines were worth $3,677,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nextech Invest Ltd. grew its stake in shares of Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after purchasing an additional 1,304,347 shares during the period. Bellevue Group AG boosted its holdings in Revolution Medicines by 4.7% during the second quarter. Bellevue Group AG now owns 4,579,300 shares of the company’s stock worth $168,472,000 after buying an additional 205,000 shares during the last quarter. Norges Bank bought a new position in Revolution Medicines during the second quarter worth about $62,584,000. Westfield Capital Management Co. LP grew its position in shares of Revolution Medicines by 55.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,649,404 shares of the company’s stock worth $60,682,000 after buying an additional 585,358 shares during the period. Finally, Vestal Point Capital LP bought a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $44,148,000. 94.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 75,000 shares of Revolution Medicines stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total value of $7,542,000.00. Following the sale, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. The trade was a 34.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark A. Goldsmith sold 15,394 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total transaction of $1,182,567.08. Following the sale, the insider directly owned 232,469 shares in the company, valued at $17,858,268.58. This trade represents a 6.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 243,792 shares of company stock valued at $19,757,740 over the last ninety days. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $97.33 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05. The firm has a market cap of $18.82 billion, a price-to-earnings ratio of -18.83 and a beta of 0.99. The stock’s 50-day moving average is $89.42 and its 200-day moving average is $61.08. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter last year, the business earned ($0.94) earnings per share. Equities analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Mizuho started coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They set an “outperform” rating and a $90.00 price objective on the stock. Needham & Company LLC lifted their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Raymond James Financial raised their price objective on Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a research note on Friday, October 17th. Finally, Wolfe Research initiated coverage on Revolution Medicines in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 target price for the company. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.